on Hematology and Cell
Therapy

Prof. Robert Zeiser will discuss the traditional and evolving concepts behind graft-versus-host disease, and how understanding of this complex phenomenon after allogeneic transplantation may help reshape the treatment paradigm that exists for decades, namely immunosuppression.

In this episode, together with Roni Shouval, we discuss the evolution of CAR T cells and their potential for cure: what does cure actually mean? We will also touch the hot topic of their potential for causing cancer, how likely it is and what this means for patients and clinicians alike.

In this episode Prof. Charles Craddock discusses the major aims of conditioning regimens prior to allogeneic stem cell transplantation and how to select proper intensity of the regimen to balance Graft versus Leukemia effect and regimen related toxicity.

In this episode, Prof. Claire Harrison discusses the central role of the spleen in myelofibrosis - from its biology and clinical significance to its dominance as trial endpoint. The conversation explores how spleen responses relate to symptoms, survival, disease heterogeneity, and the future of endpoint selection in MPN clinical trials.

In this episode Prof. Leo Luznik will describe how post-transplant cyclophosphamide as effective GvHD prophylaxis was detected and used after haploidentical allogeneic transplantation and its current and future role in HLA identical sibling, as well as in matched and mismatched unrelated stem cell transplantation.

Under the scientific leadership of Prof. Nicolaus Kröger and Dr Nico Gagelmann, the format critically examines established practices, emerging evidence, and evolving standards of care through expert dialogue. Serious in scientific content yet driven by passion, human connection, and a touch of humor, Myths & Facts creates conversations that feel real and clinically meaningful.